Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Breast cancer drug exemestane may increase fracture risk

  • Comment

Women taking the anti-breast cancer drug exemestane (Aromasin) should have regular bone monitoring to assess fracture risk because the treatment speeds up loss of bone density, a study suggests.

A total of 4,500 healthy post-menopausal women from families with a history of breast cancer took part in the study to determine the effectiveness of the drug.

The drug, which is an aromatase inhibitor and so reduces levels of oestrogen which some breast cancers feed off to grow, was extremely effective, cutting the risk of breast cancer by nearly two-thirds.

But a sub-study by bone specialists from Canada measured the bone density of 351 of the women, who were either on exemestane (Aromasin) or a placebo.

Those taking the drug suffered a high loss of bone density at the distal radius, a common fracture point in the wrist, as well as at the lower end of the tibia.

There was also an 8% reduction in the thickness of their bone’s protective outer shell, the cortical bone.

Lead study author Angela Cheung, of Toronto’s University Health Network, said that as well as regular bone monitoring, such patients should also have sufficient calcium and vitamin D supplements to tackle the increased fracture risk.


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.